At Mayo Clinic, we know the importance of laboratory testing in a patient's episode of care. Our unique combination of specialized laboratories and neurology patient care clinics gives us the ability to put into practice clinically proven, cost-effective, patient care-driven testing approaches for hundreds of neurological conditions. In addition to the latest testing, when you partner with us, you extend your network to include some of the world's leading neurology experts. Visit us at booth #1003 at AAN 2018 to discuss how our testing can integrate with your practice. View our Key Happenings at AAN 2018.

CNS Demyelinating Disease (AQP4-IgG & MOG-IgG)

Testing for AQP4 and MOG antibodies allows for the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases and distinguishes a spectrum of demyelinating disease from multiple sclerosis.

Mayo Clinic has developed the only fluorescence-activated cell sorting (FACS) live cell-binding assay that is currently available in the U.S. for antibody detection of AQP4 and MOG. FACS is recommended by international leaders in neuroimmunology for its increased sensitivity and specificity.

1/3

of AQP4-IgG (-) NMO patients positive for MOG-IgG

32%

Recurrent optic neuritis patients who are positive for AQP4-IgG or MOG-IgG

1.5x

frequency that MOG-IgG is positive compared to AQP4-IgG

MAYO CLINIC RESEARCH IN SUPPORT OF AQP4-IGG AND MOG-IGG

AQP4 Autoantibody Assay Performance in Clinical Laboratory Service Neurology, Neuroimmunology, & Neuroinflammation

FEATURED TESTS

  • CNS Demyelinating Disease Evaluation, Serum (ID: CDS1) Test Catalog | Overview PDF pdf-icon
  • Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: NMOFS) Test Catalog
  • Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: MOGFS) Test Catalog | Overview PDF pdf-icon

ADDITIONAL RESOURCES

Glial Fibrillary Acidic Protein (GFAP)-IgG

Available Clinically in 2018

A novel astrocytic autoantibody, glial fibrillary acidic protein (GFAP) has recently been described by Mayo Clinic as a biomarker of a relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapies. Seropositivity distinguishes autoimmune GFAP meningoencephalomyelitis from disorders commonly considered in the differential diagnosis.

40%

of patients with GFAP-IgG have co-existing antibodies

1/3

GFAP-IgG is 33.33% as common as NMDA-R antibody

MAYO CLINIC RESEARCH IN SUPPORT OF GFAP-IGG

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis JAMA Neurology Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients Annals of Neurology

Autoimmune Movement Disorder Evaluations

Autoimmune movement disorders encapsulate a large and diverse group of neurologic disorders occurring either in isolation or accompanying more diffuse autoimmune encephalitic illnesses. The full range of movement phenomena has been described and, as they often occur in adults, many of the presentations can mimic neurodegenerative disorders, such as Huntington disease.

Our comprehensive autoimmune movement disorder evaluations includes mGluR1 and DPPX antibodies.

53%

of autoimmune cerebellar ataxia is paraneoplastic

46%

of autoimmune cerebellar ataxia patients improve with immunotherapy

MAYO CLINIC RESEARCH IN SUPPORT OF AI MOVEMENT DISORDER TESTING

Autoimmune Movment Disorders: A Clinical and Laboratory Approach Current Neurology and Neuroscience Reports DPPX Potassium Channel Antibody: Frequency, Clinical Accompaniments, and Outcomes in 20 Patients Neurology Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes Neurology

FEATURED TESTS - Available Monday, April 23

ADDITIONAL RESOURCES

Neuromuscular and Peripheral Neuropathy NGS Testing

Our targeted approach allows for optimal mutation detection and interpretation through targeted capture techniques and unique reporting methods. This process eliminates the risk of false-negative results compared to whole-exome sequencing and other capture techniques. Disease-specific mutations will not be missed.

>100x

minimum depth of coverage

~700

average depth of coverage

FEATURED TEST

    • Neuromuscular Genetic Panels by NGS (ID: NMPAN) Test Catalog | Overview PDF pdf-icon
      • Subpanels for myopathy, muscular dystrophy, congenital myopathy, metabolic myopathy, myofibrillar myopathy, distal myopathy, emery-dreifuss, rhabdomyloysis and myopathy, distal weakness, motor neuron disease, congenital myasthenic syndromes, and skeletal muscle channelopathy

 

ADDITIONAL RESOURCES

Mayo Clinic Laboratories

Mayo Clinic Laboratories

This post was authored by the Marketing Team at Mayo Clinic Laboratories.